NASDAQ : ONCY
Oncolytics Biotech Inc. — Key statistics
Healthcare · Biotechnology · Canada
Last price 0.4254 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 54.24M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 54.24M |
| Enterprise Value | 50.58M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 16, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 127.51M |
| Shares Outstanding | 127.51M |
| Shares Change (YoY) | +33.18% |
| Shares Change (QoQ) | +6.63% |
| Owned by Insiders (%) | 1.55% |
| Owned by Institutions (%) | 3.44% |
| Float | 125.54M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 1.35 |
| Quick Ratio | 1.02 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -211.24% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -1,541.82% |
| Weighted Average Cost of Capital (WACC) | 10.96% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.29M |
| Employee Count | 29 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | 119,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.24 |
| 52-Week Price Change | -63.64% |
| 50-Day Moving Average | 0.67 |
| 200-Day Moving Average | 0.86 |
| Relative Strength Index (RSI) | 24.10 |
| Average Volume (20 Days) | 1,397,779 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 9.03M |
| Short Previous Month | 7.37M |
| Short % of Shares Out | 7.04% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 6.53 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -37.71M |
| Pretax Income | -37.34M |
| Net Income | -37.46M |
| EBITDA | -37.65M |
| EBIT | -37.71M |
| Earnings Per Share (EPS) | -$0.34 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 4.12M |
| Total Debt | 448,000 |
| Net Cash | 3.67M |
| Net Cash Per Share | $0.03 |
| Equity (Book Value) | -6.17M |
| Book Value Per Share | -0.05 |
| Working Capital | 1.84M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -26.70M |
| Capital Expenditures | -11,000 |
| Depreciation & Amortization | 64,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -26.72M |
| FCF Per Share | -$0.21 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -33.18% |
| Shareholder Yield | n/a |
| Earnings Yield | -80.07% |
| FCF Yield | -49.25% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $4.48 |
| Price Target Difference | 953.83% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | May 25, 2018 |
| Split Type | Reverse |
| Split Ratio | 1:9.5 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |